#ESMO26 上的 NIAGARA 生物标志物分析
🧬 DDR 改变（ERCC2、KMT2C、FAT1）与各组更高的 pCR 率相关。
📊 围手术期 durvalumab + NAC 改善了大多数分子亚型的 EFS，在基底鳞状和腔面型肿瘤中表观获益最大。
🔬 T 效应细胞/IFNγ 高表达肿瘤 showed 更大的 pCR 获益。
探索性发现——目前尚无经验证的生物标志物可用于筛选适合接受 durvalumab 治疗的患者。
41 浏览 · 0 赞 · 0 转发 · 0 回复
Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
https://esmocongress.esmo.orgDurvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：David H Aggen, MD PhD · x.com